Camp4 Therapeutics Corp
CAMPNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $3.5M | $652,000 | $350,000 |
| Operating income | −$52.6M | −$53.1M | −$51.9M |
| Net income | −$80.4M | −$51.8M | −$49.3M |
| Total assets | $117.8M | $78.3M | $54.9M |
| Total liabilities | $70.1M | $15.2M | $16.5M |
| Equity | $47.7M | $63.1M | −$123.7M |
| EPS (diluted) | $-2.65 | $-11.04 | $-124.80 |
| Shares out. | 20.2M | 20.1M | 460,704 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1502.4%
- Net margin
- −2298.5%
- Return on equity
- −168.5%
- Return on assets
- −68.2%
- Return on capital (ROCE)
- −51.4%
- Liabilities / assets
- 59.5%
- Debt / equity
- 1.47×
- Book value / share
- $2.37
- Revenue growth (YoY)
- 436.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -4.88distress
- Accruals / assets
- −43.2%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Balyasny Asset Management L.P.Passive (13G)May 15, 2026
- Enavate Sciences Gp, LlcActivist (13D)Mar 11, 2026
- Vivo Opportunity Fund Holdings, L.P.Passive (13G)Feb 13, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Janus Henderson Group PlcPassive (13G)Jan 8, 2026
- Coastlands Capital LpPassive (13G)Dec 11, 2025
- Northpond Ventures Ii, LpPassive (13G)Nov 14, 2025
- Ah Bio Fund I, L.P.Passive (13G)Nov 14, 2025
- Harbourvest Partners LlcPassive (13G)Oct 1, 2025
- 5am Ventures Vi, L.P.Activist (13D)Sep 11, 2025
- Polaris Management Co. Vii, L.L.C.Activist (13D)Sep 11, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Polaris Management Co. Vii, L.L.C.10% owner | Sep 11, 2025 | Buy | 1.2M | $1.53 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 322,402 | 3.5 | -28.4% |
| Apr 30, 2026 | 450,462 | 6.5 | -3.8% |
| Apr 15, 2026 | 468,369 | 6.5 | +13.1% |
| Mar 31, 2026 | 414,235 | 3.2 | -14.3% |
| Mar 13, 2026 | 483,060 | 1.0 | -6.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 14, 2026
- Results of operationsMay 7, 2026
- Director / officer changeMar 24, 2026
- Completed an acquisition or disposition · Regulation FD disclosureMar 5, 2026
- Regulation FD disclosureJan 9, 2026
- Entered a material agreement · Terminated a material agreementDec 23, 2025
- Entered a material agreementDec 18, 2025
- Entered a material agreement · Regulation FD disclosureDec 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.